EGFR and non-small cell lung carcinoma: It has been suggested that other relatively frequent mutations like EGFR and PI3KCA activations correlate with the in situ proliferation and metabolic alterations (e.g., in non-small cell lung cancer — NSCLCs and breast carcinomas).